Recursion Pharmaceuticals (MEX:RXRX) Other Operating Expense: MXN-16.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RXRX Recursion Pharmaceuticals Inc MEX:RXRX
43 GF Score
Price MXN59.39
GF Value MXN50.45
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Other Operating Expense?

Recursion Pharmaceuticals MEX:RXRX +7.98% 43 Other Operating Expense is MXN-16.4 Mil as of Jun. 2026. GuruFocus rates MEX:RXRX with a GF Score™ of 43/100 and a GF Value™ of MXN50.45 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Recursion Pharmaceuticals's Other Operating Expense for the three months ended in Jun. 2026 was MXN-6.4 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-16.4 Mil.

Recursion Pharmaceuticals's quarterly Other Operating Expense increased from Dec. 2025 (MXN-3.4 Mil) to Mar. 2026 (MXN-3.1 Mil) but then declined from Mar. 2026 (MXN-3.1 Mil) to Jun. 2026 (MXN-6.4 Mil).

Recursion Pharmaceuticals's annual Other Operating Expense increased from Dec. 2023 (MXN-11.9 Mil) to Dec. 2024 (MXN-7.3 Mil) but then declined from Dec. 2024 (MXN-7.3 Mil) to Dec. 2025 (MXN-7.7 Mil).

Recursion Pharmaceuticals Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Other Operating Expense Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial -3.65 -3.16 -11.86 -7.32 -7.65

Recursion Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 -3.52 -3.37 -3.08 -6.40
MEX:RXRX
43GF Score
Recursion Pharmaceuticals Inc MEX:RXRX
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-16.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of MXN-16.4 Mil mean?
Recursion Pharmaceuticals (MEX:RXRX) has a Other Operating Expense of MXN-16.4 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Other Operating Expense too high?
Recursion Pharmaceuticals' current Other Operating Expense is MXN-16.4 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 43/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Other Operating Expense compare to INVA and TSHA?
Recursion Pharmaceuticals' Other Operating Expense of MXN-16.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Other Operating Expense is MXN-16.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN50.45, compared to a current price of MXN59.39 — trading 17.7% above its estimated fair value. The current Other Operating Expense is MXN-16.4 Mil. Recursion Pharmaceuticals' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current Other Operating Expense is MXN-16.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be overvalued. The current stock price of MXN59.39 is trading 17.7% above its estimated GF Value™ of MXN50.45. GuruFocus considers Recursion Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for MEX:RXRX:

  • Other Operating Expense: MXN-16.4 Mil
  • GF Value™: MXN50.45 vs. price of MXN59.39 (17.7% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:USA
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
43GF Score

Get the complete analysis for MEX:RXRX

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN59.39
Price
MXN50.45
GF Value